NO2982982T3 - - Google Patents

Info

Publication number
NO2982982T3
NO2982982T3 NO14290232A NO14290232A NO2982982T3 NO 2982982 T3 NO2982982 T3 NO 2982982T3 NO 14290232 A NO14290232 A NO 14290232A NO 14290232 A NO14290232 A NO 14290232A NO 2982982 T3 NO2982982 T3 NO 2982982T3
Authority
NO
Norway
Application number
NO14290232A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2982982T3 publication Critical patent/NO2982982T3/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO14290232A 2014-08-06 2014-08-06 NO2982982T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14290232.9A EP2982982B1 (en) 2014-08-06 2014-08-06 Method of screening of compounds using membrane STIM1

Publications (1)

Publication Number Publication Date
NO2982982T3 true NO2982982T3 (pl) 2018-03-03

Family

ID=51398585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14290232A NO2982982T3 (pl) 2014-08-06 2014-08-06

Country Status (11)

Country Link
US (2) US20170219588A1 (pl)
EP (2) EP2982982B1 (pl)
JP (2) JP6754751B2 (pl)
CN (2) CN110051836B (pl)
CA (1) CA2952159C (pl)
DK (1) DK2982982T3 (pl)
ES (1) ES2654674T3 (pl)
NO (1) NO2982982T3 (pl)
PL (1) PL2982982T3 (pl)
PT (1) PT2982982T (pl)
WO (1) WO2016020274A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3714942A1 (en) 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
EP3715848A1 (en) * 2019-03-25 2020-09-30 Université de Bretagne Occidentale (U.B.O.) Substance interacting with c terminal fragment of the stim1 fraction localized to the plasma membrane of the cells, for its use in the treatment of cancers, and in screening and diagnostic methods
EP3714943A1 (en) 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
WO2022162015A1 (en) * 2021-01-26 2022-08-04 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601335B2 (en) * 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
CA2688417C (en) * 2007-05-24 2017-04-25 Calcimedica, Inc. Calcium channel proteins and uses thereof
EP2244700A4 (en) * 2007-07-10 2011-03-02 Immune Disease Inst Inc STIM (STROMAL INTERACTING MOLECULE) KNOCKOUT MOUSE AND ITS USES
US20110136123A1 (en) * 2007-08-15 2011-06-09 Universite De Sherbrooke Alternative splicing gene variants in cancer
RU2465272C2 (ru) * 2007-09-10 2012-10-27 КалсиМедика, Инк. Соединения, моделирующие внутриклеточный кальций
EP2103311A1 (en) * 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
US20120165265A1 (en) * 2009-02-26 2012-06-28 Dolmetsch Ricardo E Calcium Signaling Modulators Involving STIM and ORAI Proteins
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
AU2012292930B2 (en) * 2011-08-10 2017-08-03 Biommune Technologies, Inc. Methods and compositions for modulating voltage-gated calcium channel function
CN102433383B (zh) * 2011-12-19 2015-07-08 上海吉凯基因化学技术有限公司 人stim1基因的用途及其相关药物

Also Published As

Publication number Publication date
EP3177929B1 (en) 2018-05-09
WO2016020274A1 (en) 2016-02-11
CN110051836A (zh) 2019-07-26
CN106716130A (zh) 2017-05-24
ES2654674T3 (es) 2018-02-14
CA2952159C (en) 2022-08-30
JP2019214576A (ja) 2019-12-19
JP2017531164A (ja) 2017-10-19
EP2982982A1 (en) 2016-02-10
EP2982982B1 (en) 2017-10-04
CA2952159A1 (en) 2016-02-11
DK2982982T3 (en) 2018-01-08
PL2982982T3 (pl) 2018-03-30
PT2982982T (pt) 2018-01-03
US20190154690A1 (en) 2019-05-23
JP6754751B2 (ja) 2020-09-16
CN106716130B (zh) 2019-03-29
CN110051836B (zh) 2023-05-26
US20170219588A1 (en) 2017-08-03
JP6861246B2 (ja) 2021-04-21
EP3177929A1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
BR112016017664A2 (pl)
BR112016017979A2 (pl)
BR112016015519A2 (pl)
BR112016003131A2 (pl)
BR112016016490A2 (pl)
BR112016016546A2 (pl)
BR112016018264A2 (pl)
BR112016017103A2 (pl)
BR112016017031A2 (pl)
BR112016016421A2 (pl)
BR112016012568A2 (pl)
BR112016016558A2 (pl)
BR112016015798A2 (pl)
BR112016017960A2 (pl)
BR112016015915A2 (pl)
BR112016018252A2 (pl)
BR112016016468A2 (pl)
BR112016017356A2 (pl)
BR112016016459A2 (pl)
BR112016003522A2 (pl)
BR112016014482A2 (pl)
BR112016018021A2 (pl)
BR112016015054A2 (pl)
BR112016017675A2 (pl)
BR112016015896A2 (pl)